Charles River Labs Jumps 33.3% in a Month on Strong Q2

Earnings

โดย Zacks Investment Research·

Summary · why it matters

Charles River Laboratories International shares have risen 33.3% over the past four weeks, lifted by second-quarter earnings that beat estimates and raised guidance. The company reported non-GAAP earnings of $3.02 per share, down 3.2% year over year but 17.6% above the Zacks Consensus Estimate, while revenues of $1 billion declined 2.7% but topped consensus by 3%. Management raised full-year non-GAAP earnings guidance to $11.15-$11.45 per share from $10.80-$11.30. Discovery and Safety Assessment organic revenues rose 0.2%, the segment's first organic growth since the third quarter of 2023, with net bookings up 12.6% sequentially to $701 million and backlog at $1.97 billion. However, Research Models and Services organic revenues fell 1.4%, and the stock trades at 24.06 times forward earnings versus a five-year median of 18.44 times, leaving less room for execution missteps.

Charles River Laboratories ▲